Literature DB >> 24888730

Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma.

Laurie Gashin1, Elliot Tapper, Atinuke Babalola, Kuan-Chi Lai, Rebecca Miksad, Raza Malik, Eric Cohen.   

Abstract

BACKGROUND: The multidisciplinary tumour conference (MTC) represents the standard of care in the management of hepatocellular carcinoma (HCC). Clinical outcomes in relation to adherence and non-adherence to MTC recommendations have not been studied.
METHODS: A total of 137 patients with HCC and cirrhosis whose cases were submitted to a first MTC discussion between 1 January 2009 and 31 December 2010 were identified. Clinical data, management recommendations, adherence, treatment regimens and overall survival were reviewed.
RESULTS: There were 419 MTC discussions on 137 patients with cirrhosis and HCC. The MTC recommendations made in 145 discussions on 90 separate patients were not followed. Patient-related reasons for deviation from MTC recommendations included failure to attend for follow-up (n = 24, 16.6%), clinical deterioration (n = 19, 13.1%) and patient preference (n = 13, 9.0%). Physician-related reasons for discordance included treating physician preference (n = 43, 29.7%) and finding that the patient was not a candidate for the recommended intervention (n = 37, 25.5%). After the first MTC discussion, 62.0% of patients received the recommended treatment; these patients were more likely to be alive at 1 year compared with those who did not receive the recommended treatment (P = 0.007). More of the patients who followed recommendations underwent liver transplantation (25.6% versus 14.4%; P = 0.10).
CONCLUSIONS: There are patient-related as well as physician-related reasons for non-adherence to recommendations. Non-adherence affects clinical outcomes and can be avoided in selected cases.
© 2014 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2014        PMID: 24888730      PMCID: PMC4487752          DOI: 10.1111/hpb.12280

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  18 in total

1.  A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.

Authors:  Jiwei Huang; Lvnan Yan; Zheyu Cheng; Hong Wu; Liang Du; Jinzhou Wang; Yinglong Xu; Yong Zeng
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

2.  Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization.

Authors:  Kenneth S Chok; Kelvin K Ng; Ronnie T P Poon; Chi Ming Lam; Jimmy Yuen; Wai Kuen Tso; Sheung Tat Fan
Journal:  Arch Surg       Date:  2006-12

3.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

Review 4.  Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma.

Authors:  J R L Maggs; A R Suddle; V Aluvihare; M A Heneghan
Journal:  Aliment Pharmacol Ther       Date:  2012-03-20       Impact factor: 8.171

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Hepatocellular carcinoma: multimodality management.

Authors:  K K Christians; H A Pitt; W S Rilling; J Franco; F A Quiroz; M B Adams; J R Wallace; E J Quebbeman
Journal:  Surgery       Date:  2001-10       Impact factor: 3.982

7.  Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation.

Authors:  Jason T Heckman; Michael B Devera; J Wallis Marsh; Paulo Fontes; Nikhil B Amesur; Shane E Holloway; Michael Nalesnik; David A Geller; Jennifer L Steel; T Clark Gamblin
Journal:  Ann Surg Oncol       Date:  2008-08-12       Impact factor: 5.344

Review 8.  Review article: the management of hepatocellular carcinoma.

Authors:  R Cabrera; D R Nelson
Journal:  Aliment Pharmacol Ther       Date:  2009-11-19       Impact factor: 8.171

9.  Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival.

Authors:  Tammy T Chang; Rajiv Sawhney; Alexander Monto; J Ben Davoren; Jacob G Kirkland; Lygia Stewart; Carlos U Corvera
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

Review 10.  Multidisciplinary management of hepatocellular carcinoma.

Authors:  William S Rilling; Alain Drooz
Journal:  J Vasc Interv Radiol       Date:  2002-09       Impact factor: 3.464

View more
  8 in total

Review 1.  Effects of volume on outcome in hepatobiliary surgery: a review with guidelines proposal.

Authors:  Eloisa Franchi; Matteo Donadon; Guido Torzilli
Journal:  Glob Health Med       Date:  2020-10-31

Review 2.  Multidisciplinary Approach to HCC Management: How Can This Be Done?

Authors:  Melissa M Gadsden; David E Kaplan
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 3.  Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement.

Authors:  Luis Antonio Díaz; Gustavo Ayares; Jorge Arnold; Francisco Idalsoaga; Oscar Corsi; Marco Arrese; Juan Pablo Arab
Journal:  Curr Treat Options Gastroenterol       Date:  2022-06-16

4.  Translation of oncology multidisciplinary team meeting (MDM) recommendations into clinical practice.

Authors:  Shalini K Vinod; Nisali T Wellege; Sara Kim; Kirsten J Duggan; Mirette Ibrahim; Jesmin Shafiq
Journal:  BMC Health Serv Res       Date:  2021-05-14       Impact factor: 2.655

5.  "A rising tide lifts all boats": establishing a multidisciplinary genomic tumor board for breast cancer patients with advanced disease.

Authors:  Michelle L McGowan; Roselle S Ponsaran; Paula Silverman; Lyndsay N Harris; Patricia A Marshall
Journal:  BMC Med Genomics       Date:  2016-11-21       Impact factor: 3.063

6.  Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges.

Authors:  Federico Piñero; Jaime Poniachik; Ezequiel Ridruejo; Marcelo Silva
Journal:  World J Gastroenterol       Date:  2018-10-07       Impact factor: 5.742

7.  Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients.

Authors:  Dong Hyun Sinn; Gyu-Seong Choi; Hee Chul Park; Jong Man Kim; Honsoul Kim; Kyoung Doo Song; Tae Wook Kang; Min Woo Lee; Hyunchul Rhim; Dongho Hyun; Sung Ki Cho; Sung Wook Shin; Woo Kyoung Jeong; Seong Hyun Kim; Jeong Il Yu; Sang Yun Ha; Su Jin Lee; Ho Yeong Lim; Kyunga Kim; Joong Hyun Ahn; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Jae-Won Joh; Hyo Keun Lim; Seung Woon Paik
Journal:  PLoS One       Date:  2019-01-14       Impact factor: 3.240

8.  Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis.

Authors:  Chenli Zhang; Chen Zhang; Tianyu Zhang; Hua Liu; Jie Zhong; Zhengting Wang; Liying Wang; Liwen Hong
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.